Why the study?
Is circulating FABP4 an independent prognostic biomarker that improves risk stratification in patients with acute ischemic stroke?
Population
Patients with acute ischemic stroke
Design
Cohort
Authors
Loading...
Does not yet support changing stroke risk stratification; leaves open FABP4's role pending prospective validation.
Is circulating FABP4 an independent prognostic biomarker that improves risk stratification in patients with acute ischemic stroke?
Circulating FABP4 serves as an independent prognostic biomarker that improves risk stratification in acute ischemic stroke patients.
Tu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: